Fo
Forty Seven (Gilead)
Menlo Park CAFounded 2015100 employees
Private CapbiotechAcquiredOncologyHematology
Platform: CD47 magrolimab
Market Cap
N/A
All Drugs
2
Clinical Trials
3
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Mavubrutinib | FOR-8872 | Phase 3 | 1 | GLP-1R | Urothelial CaFL | ||
| Nidazumab | FOR-6896 | Phase 1/2 | 2 | KRASG12C | MyelofibrosisADPKD |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)